The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
Subscribe To Our Newsletter & Stay Updated
